Natera (NASDAQ:NTRA) Lowered to Sell at StockNews.com

by · The Cerbat Gem

StockNews.com downgraded shares of Natera (NASDAQ:NTRA – Free Report) from a hold rating to a sell rating in a research report released on Friday morning.

Other research analysts have also issued research reports about the company. Robert W. Baird increased their target price on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Canaccord Genuity Group increased their target price on Natera from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, August 27th. UBS Group decreased their target price on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, August 9th. BTIG Research raised their price objective on Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Leerink Partners raised their price objective on Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $124.44.

Check Out Our Latest Report on NTRA

Natera Price Performance

Shares of Natera stock opened at $117.67 on Friday. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $14.55 billion, a PE ratio of -48.03 and a beta of 1.53. The business’s 50-day moving average price is $123.24 and its 200-day moving average price is $111.24. Natera has a 12 month low of $36.90 and a 12 month high of $133.54.

Natera (NASDAQ:NTRA – Get Free Report) last issued its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. During the same period in the prior year, the business posted ($0.97) EPS. Natera’s quarterly revenue was up 58.1% compared to the same quarter last year. Sell-side analysts forecast that Natera will post -1.96 EPS for the current fiscal year.

Insider Transactions at Natera

In other Natera news, CFO Michael Burkes Brophy sold 691 shares of the business’s stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $118.81, for a total transaction of $82,097.71. Following the completion of the sale, the chief financial officer now owns 72,709 shares of the company’s stock, valued at approximately $8,638,556.29. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Natera news, CFO Michael Burkes Brophy sold 691 shares of the business’s stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $118.81, for a total transaction of $82,097.71. Following the completion of the sale, the chief financial officer now owns 72,709 shares of the company’s stock, valued at approximately $8,638,556.29. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Steven Leonard Chapman sold 4,084 shares of the business’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $102.77, for a total value of $419,712.68. Following the sale, the chief executive officer now directly owns 206,293 shares of the company’s stock, valued at $21,200,731.61. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,149 shares of company stock worth $6,007,018 in the last ninety days. Insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Natera

A number of hedge funds have recently made changes to their positions in the business. Quent Capital LLC boosted its stake in Natera by 3.2% during the first quarter. Quent Capital LLC now owns 3,205 shares of the medical research company’s stock valued at $293,000 after buying an additional 99 shares during the last quarter. GAMMA Investing LLC raised its position in Natera by 32.7% during the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares during the period. Moss Adams Wealth Advisors LLC raised its position in Natera by 5.4% during the third quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock valued at $336,000 after purchasing an additional 135 shares during the period. Private Advisor Group LLC raised its position in Natera by 5.2% during the third quarter. Private Advisor Group LLC now owns 2,721 shares of the medical research company’s stock valued at $346,000 after purchasing an additional 135 shares during the period. Finally, Lake Street Advisors Group LLC raised its position in Natera by 7.4% during the third quarter. Lake Street Advisors Group LLC now owns 2,250 shares of the medical research company’s stock valued at $286,000 after purchasing an additional 156 shares during the period. Institutional investors own 99.90% of the company’s stock.

About Natera

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

See Also